Tonsillitis Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Tonsillitis — inflammation of the palatine tonsils located at the back of the throat — is one of the most common infections encountered in primary care and ENT practice, particularly in children aged 3–15 years. The tonsils are lymphoid tissue masses forming part of Waldeyer's ring, playing an immune surveillance role during early childhood that diminishes in adolescence and adulthood. Tonsillitis is classified as acute (a discrete episode lasting less than two weeks), recurrent acute (repeated episodes meeting frequency criteria), and chronic tonsillitis (persistent low-grade tonsillar inflammation with chronic throat discomfort and halitosis).

The majority of acute tonsillitis cases are viral in aetiology — rhinovirus, adenovirus, influenza, Epstein-Barr virus (infectious mononucleosis) — and do not require antibiotic treatment. Group A beta-haemolytic Streptococcus (Streptococcus pyogenes, GAS) accounts for 30–40% of cases in children and 5–15% in adults, and is the only pathogen for which antibiotic treatment significantly reduces symptom duration, prevents complications (peritonsillar abscess, rheumatic fever), and reduces transmission. Clinical scoring systems — the Centor criteria and FeverPAIN score — guide the decision to test and/or treat with antibiotics based on clinical features: tonsillar exudate, absence of cough, fever, and swollen anterior cervical lymph nodes.

For patients with recurrent tonsillitis meeting evidence-based frequency criteria, or tonsillar hypertrophy causing obstructive symptoms, tonsillectomy remains one of the most commonly performed surgical procedures globally. The AAO-HNS and SIGN guidelines define the surgical threshold for adult tonsillectomy as seven or more episodes of clinically significant tonsillitis in one year, five or more per year for two consecutive years, or three or more per year for three consecutive years (Paradise criteria).

Acute bacterial tonsillitis caused by Group A Streptococcus is treated with a 10-day course of phenoxymethylpenicillin (penicillin V) — the antibiotic of choice — which reduces duration of symptoms by one to two days, prevents streptococcal complications (peritonsillar abscess, quinsy, post-streptococcal glomerulonephritis, rheumatic fever), and reduces infectivity. Amoxicillin is equally effective but must not be used when Epstein-Barr virus (EBV/glandular fever) is suspected as it causes a characteristic widespread maculopapular rash in 90% of EBV-infected patients.

Peritonsillar abscess (quinsy) — a collection of pus around the tonsil causing severe unilateral throat pain, trismus (difficulty opening the mouth), and deviation of the uvula — is treated by urgent drainage (needle aspiration or incision and drainage) under local anaesthesia and intravenous antibiotics, followed by interval tonsillectomy six to eight weeks later to prevent recurrence. Tonsillar hypertrophy causing obstructive sleep apnoea in children is the primary paediatric indication for tonsillectomy — combined adenotonsillectomy achieves resolution of OSA in 70–80% of healthy children. Chronic tonsillitis with persistent throat discomfort, frequent malodorous tonsil stones (tonsilloliths), and halitosis is addressed by tonsillectomy when quality of life is significantly impaired.

Medical treatment of acute tonsillitis is appropriate for all patients presenting with tonsillitis regardless of age. Antibiotic treatment decisions should be guided by clinical scoring (Centor or FeverPAIN) or rapid antigen test and throat culture to target true GAS infection and avoid unnecessary antibiotic exposure for viral tonsillitis. Analgesics (paracetamol, ibuprofen) and adequate hydration are the cornerstone of symptomatic management in all cases.

Tonsillectomy candidacy in adults follows the Paradise criteria described above. For children, combined adenotonsillectomy is indicated primarily for obstructive sleep apnoea with significant tonsillar hypertrophy. Less stringent frequency criteria (three or more qualifying episodes per year for three years) may be appropriate for children with modifying factors: peritonsillar abscess history, PFAPA syndrome (periodic fever with aphthous stomatitis, pharyngitis, and adenitis), or documented streptococcal carriage causing family transmission. Tonsillectomy is not indicated for isolated acute tonsillitis without recurrence, asymptomatic tonsillar hypertrophy without obstruction or infection, or incidental tonsillar asymmetry without clinical concerns. Contraindications include active acute tonsillitis (surgery deferred until resolved), coagulopathy requiring perioperative management, and medical conditions precluding general anaesthesia.

Antibiotic treatment of confirmed or highly suspected GAS tonsillitis uses phenoxymethylpenicillin (penicillin V) 500 mg twice daily for ten days in adults, or 12.5 mg/kg twice daily in children. A ten-day course achieves superior bacteriological eradication compared to shorter courses. Cefalexin (cephalexin) or clarithromycin are alternatives for penicillin-allergic patients. Amoxicillin-clavulanate is reserved for treatment failure or mixed oral flora tonsillitis. Systemic corticosteroids (dexamethasone 10 mg single IV or oral dose) reduce pain and time to return to normal swallowing when prescribed alongside antibiotics for severe acute tonsillitis.

Tonsillectomy is performed under general anaesthesia as a day procedure or with overnight monitoring for severe OSA cases. Standard cold steel (guillotine or dissection) tonsillectomy remains the benchmark technique but is associated with significant postoperative pain as raw tonsillar fossae must heal by secondary intention. Electrocautery (diathermy) dissection reduces blood loss but increases thermal tissue damage and postoperative pain. Coblation tonsillectomy uses bipolar radiofrequency plasma energy at low temperature (40–70°C) to dissolve tonsillar tissue with less thermal injury, providing evidence for reduced postoperative pain and earlier return to diet in multiple RCTs. Laser tonsillectomy, microdebrider intracapsular tonsillotomy (subtotal removal leaving a residual tonsillar capsule), and harmonic scalpel techniques are available at specialist centres with specific clinical advantages.

Antibiotic treatment of confirmed GAS tonsillitis achieves symptomatic improvement approximately one to two days faster than placebo and reliably prevents peritonsillar abscess and post-streptococcal complications. Appropriate antibiotic selection and prescribing practices reduce antibiotic resistance development. Tonsillectomy for recurrent tonsillitis achieves a significant reduction in tonsillitis episodes in the first post-operative year: meta-analyses report average reductions of 3–3.5 tonsillitis episodes per year compared to watchful waiting, representing an 85–90% reduction in throat infection frequency.

The clinical trial evidence (Paradise trials) demonstrates that children with the most severe tonsillitis burden (seven or more qualifying episodes per year) benefit most from tonsillectomy, while children with fewer episodes may have equivalent outcomes to watchful waiting by year two as natural disease remission occurs. Adult tonsillectomy achieves disease resolution in 95% of patients meeting surgical criteria. Tonsillectomy for OSA resolves obstructive sleep apnoea in 70–80% of otherwise healthy children, with reductions in bedwetting, behavioural problems, and school performance difficulties attributed to sleep disruption.

Tonsillectomy carries the well-characterised risk of post-operative haemorrhage: primary haemorrhage (within 24 hours, during surgery or immediate recovery) managed intraoperatively, and secondary haemorrhage (five to ten days post-operatively as the tonsillar eschar separates) occurring in approximately 2–4% of patients and requiring emergency hospital attendance, possible transfusion, and occasionally return to theatre for surgical haemostasis. Patients and parents must be clearly educated about bleeding warning signs and emergency attendance criteria before discharge.

Postoperative pain is the major morbidity of tonsillectomy, particularly days three to five as the white slough in the tonsillar fossae thickens before separation. Inadequate analgesia leads to dehydration from oral intake refusal, a preventable cause of readmission. Regular paracetamol and ibuprofen alternated every four hours throughout the ten-day recovery prevents this. Post-operative nausea and vomiting from general anaesthesia, throat oedema causing transient snoring, taste disturbance from palate manipulation, and microbiome changes from post-operative antibiotic courses are recognised but generally transient adverse effects. Velopharyngeal insufficiency and nasopharyngeal stenosis are extremely rare with tonsillectomy alone (without concurrent extensive palatal surgery).

Post-tonsillectomy patients follow a clear recovery protocol. Regular analgesia — paracetamol 1 g and ibuprofen 400 mg alternated every four to six hours — should be taken around the clock for the first seven days regardless of pain level, preventing inadequate analgesia from inadequate intake. Oral intake including cold fluids and soft foods should be encouraged early; a liquid-only diet is not necessary and delays healing. Adequate hydration is essential; if the patient cannot swallow adequate fluids, emergency assessment is required.

Return to school or work is typically possible at ten to fourteen days. Strenuous activity, contact sports, and heavy lifting should be avoided for two weeks. Air travel is safe from two weeks post-operatively. ENT follow-up is not always required after uncomplicated tonsillectomy in adults; review at three to four weeks is appropriate for children or where intraoperative findings are recorded. Parents should return to emergency services immediately if bright red bleeding from the mouth, high fever, inability to swallow any fluids, or signs of systemic sepsis develop. Patients should avoid aspirin and non-steroidal anti-inflammatory drugs known to increase bleeding tendency in the first two weeks, using paracetamol-based preparations.

Tonsillectomy in the United States as a day surgical procedure costs $4,000–$9,000 all-inclusive (surgeon, anaesthesia, facility). Paediatric tonsillectomy for sleep apnoea or recurrent infection is covered by most insurance plans when medical necessity documentation is provided. In the UK, tonsillectomy on the NHS is available for qualifying patients with waiting times typically six to twelve months; private tonsillectomy costs £2,000–£4,500. In Europe, tonsillectomy costs €1,500–€4,000 in private settings.

International patients can access tonsillectomy at significantly lower cost at accredited ENT centres worldwide. Tonsillectomy in India costs $500–$1,500 at quality ENT centres in major hospitals. Thailand and Malaysia offer the procedure at $800–$2,500. Adenotonsillectomy for paediatric OSA at accredited centres in India and Thailand costs $1,000–$3,000 — compared to $5,000–$10,000 in the US. These centres use equivalent surgical techniques (coblation or cold steel) and have paediatric anaesthesiology capability. Brief hospital stay and rapid recovery make tonsillectomy one of the more practical medical tourism procedures.

For acute tonsillitis, watchful waiting with analgesia and hydration is appropriate for mild viral tonsillitis, avoiding unnecessary antibiotic prescribing. Throat lozenges and antiseptic gargles provide symptomatic relief without antibiotic risks. For recurrent tonsillitis not meeting tonsillectomy criteria, antibiotic prophylaxis (low-dose penicillin V for one year) has been studied but is not widely recommended due to limited efficacy and antibiotic resistance concerns.

Tonsil stone (tonsillolith) formation in patients with chronic tonsillitis can be managed conservatively with oral irrigators and water flossing to mechanically clear crypts, nasal saline irrigation to reduce postnasal drip, and probiotic throat sprays, deferring tonsillectomy in patients who respond. For tonsillar hypertrophy causing mild snoring without significant OSA, mandibular advancement devices are a non-surgical alternative to tonsillectomy for sleep-disordered breathing. Tonsil cryptolysis using laser or coblation to ablate the tonsillar surface and crypt openings is a clinic procedure for tonsillolith management and mild chronic tonsillitis, representing a less invasive alternative to complete tonsillectomy in selected patients.